NasdaqGM:ORKABiotechs
Oruka’s Expanded IL-23 Rights Reshape Pipeline Options And Partner Potential
Oruka Therapeutics (NasdaqGM:ORKA) has amended its IL-23 License Agreement with Paragon Therapeutics.
The revised agreement broadens therapeutic, prophylactic, palliative, and diagnostic uses tied to Oruka’s IL-23 pipeline.
The amendment also changes certain restrictions related to clinical trials and future licensing terms.
For Oruka Therapeutics, a company focused on IL-23 directed therapies, this move widens the scope of how its existing science can be used across disease treatment,...


